Sep 22 2014 Published by drugmonkey under Grant Review, Grantsmanship, NIH funding
Reviewing a competing continuation of a longitudinal human subjects study always has a little bit of a whiff of extortion to it. I'm not saying this is intentional but......
The sunk cost fallacy is a monster.
3 responses so far
I have a CDA. From what I've seen and heard so far, the sunk cost fallacy could be my key to a bright and shiny future lined with R01s.
Abstract: If you don't fund this competing continuation, PATIENTS WILL DIE!!!!!!!
longitudinal in animals is qualitatively the same, just slightly less expensive.
DrugMonkey is an NIH-funded researcher who blogs about careerism in science. And occasionally about the science of drug use.
Site Admin | Theme by Niyaz
Drugmonkey Copyright © 2017 All Rights Reserved